Increased AKR1C1/2/3 levels are observed in cisplatin-resistant bladder cancer and colon cancer cell lines, leukemia cells continuously treated with daunorubicin, and in cisplatin-resistant ovarian cancers [54–57]. Here, AKR1C1 is linked to leukemia.